Please assess the completion status of the following clinical trial:

Trial Title: Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants at least 18 years old~* Participants with moderate to severe RA not previously treated with TCZ (Intravenous \[IV\] or SC) for whom the rheumatologists have decided to initiate TCZ SC treatment as monotherapy or in combination with another conventional synthetic disease modifying anti-rheumatic drugs (csDMARD)~Exclusion Criteria:~* Participants taking part in a clinical trial on RA at the time of inclusion~* Participants with a contra-indication to TCZ SC therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants with Moderate to Severe RA (Type: None): Participants with moderate or severe RA, naïve to TCZ treatment (IV or SC), and who have no contra-indication to TCZ SC therapy as per the local label are included.

Based on this trial design, predict the completion outcome and termination type (if applicable).